Use of pegylated interferon in hypereosinophilic syndrome

Joseph H. Butterfield; Catherine R. Weiler

doi:10.1016/j.leukres.2011.09.026

Use of pegylated interferon in hypereosinophilic syndrome

Joseph H. Butterfield, Catherine R. Weiler

Allergic Diseases

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Scant information exists about pegylated interferons (PEG-IFNs) use for treating hypereosinophilic syndrome (HES). We describe 6 patients with HES-1 patient with a newly identified chromosomal abnormality-who received PEG-IFNs. PEG-IFN alpha-2b replaced interferon (IFN) alpha-2b for 4 patients and was initial treatment of 2 patients. PEG-IFN alpha-2a was substituted when PEG-IFN alpha-2b became unavailable. PEG-IFNs were well tolerated and controlled eosinophilia. The dose of PEG-IFNs often could be tapered and the interval between doses lengthened beyond 7. days. Adverse effects included dose-related increases in liver enzyme levels, hair loss, mild lymphopenia, and neutropenia. PEG-IFNs are effective treatment of HES.

Original language	English (US)
Pages (from-to)	192-197
Number of pages	6
Journal	Leukemia Research
Volume	36
Issue number	2
DOIs	https://doi.org/10.1016/j.leukres.2011.09.026
State	Published - Feb 2012

Keywords

Eosinophilia
Hypereosinophilic syndrome
Immunoglobulins
Interferon
Methoxy polyethylene glycol

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2011.09.026

Cite this

@article{b3a8a45f8b664a98a6e4614aa7989b12,

title = "Use of pegylated interferon in hypereosinophilic syndrome",

abstract = "Scant information exists about pegylated interferons (PEG-IFNs) use for treating hypereosinophilic syndrome (HES). We describe 6 patients with HES-1 patient with a newly identified chromosomal abnormality-who received PEG-IFNs. PEG-IFN alpha-2b replaced interferon (IFN) alpha-2b for 4 patients and was initial treatment of 2 patients. PEG-IFN alpha-2a was substituted when PEG-IFN alpha-2b became unavailable. PEG-IFNs were well tolerated and controlled eosinophilia. The dose of PEG-IFNs often could be tapered and the interval between doses lengthened beyond 7. days. Adverse effects included dose-related increases in liver enzyme levels, hair loss, mild lymphopenia, and neutropenia. PEG-IFNs are effective treatment of HES.",

keywords = "Eosinophilia, Hypereosinophilic syndrome, Immunoglobulins, Interferon, Methoxy polyethylene glycol",

author = "Butterfield, {Joseph H.} and Weiler, {Catherine R.}",

year = "2012",

month = feb,

doi = "10.1016/j.leukres.2011.09.026",

language = "English (US)",

volume = "36",

pages = "192--197",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "2",

}

TY - JOUR

T1 - Use of pegylated interferon in hypereosinophilic syndrome

AU - Butterfield, Joseph H.

AU - Weiler, Catherine R.

PY - 2012/2

Y1 - 2012/2

N2 - Scant information exists about pegylated interferons (PEG-IFNs) use for treating hypereosinophilic syndrome (HES). We describe 6 patients with HES-1 patient with a newly identified chromosomal abnormality-who received PEG-IFNs. PEG-IFN alpha-2b replaced interferon (IFN) alpha-2b for 4 patients and was initial treatment of 2 patients. PEG-IFN alpha-2a was substituted when PEG-IFN alpha-2b became unavailable. PEG-IFNs were well tolerated and controlled eosinophilia. The dose of PEG-IFNs often could be tapered and the interval between doses lengthened beyond 7. days. Adverse effects included dose-related increases in liver enzyme levels, hair loss, mild lymphopenia, and neutropenia. PEG-IFNs are effective treatment of HES.

AB - Scant information exists about pegylated interferons (PEG-IFNs) use for treating hypereosinophilic syndrome (HES). We describe 6 patients with HES-1 patient with a newly identified chromosomal abnormality-who received PEG-IFNs. PEG-IFN alpha-2b replaced interferon (IFN) alpha-2b for 4 patients and was initial treatment of 2 patients. PEG-IFN alpha-2a was substituted when PEG-IFN alpha-2b became unavailable. PEG-IFNs were well tolerated and controlled eosinophilia. The dose of PEG-IFNs often could be tapered and the interval between doses lengthened beyond 7. days. Adverse effects included dose-related increases in liver enzyme levels, hair loss, mild lymphopenia, and neutropenia. PEG-IFNs are effective treatment of HES.

KW - Eosinophilia

KW - Hypereosinophilic syndrome

KW - Immunoglobulins

KW - Interferon

KW - Methoxy polyethylene glycol

UR - http://www.scopus.com/inward/record.url?scp=84855188876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855188876&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2011.09.026

DO - 10.1016/j.leukres.2011.09.026

M3 - Article

C2 - 22118911

AN - SCOPUS:84855188876

SN - 0145-2126

VL - 36

SP - 192

EP - 197

JO - Leukemia Research

JF - Leukemia Research

IS - 2

ER -

Use of pegylated interferon in hypereosinophilic syndrome

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this